2561 (2561) Fair Value & Analysis

Healthcare · Market cap HK$2.8B

2 2561 2561 · HK

PriceHK$25.00

Fair ValueHK$6.10

Upside-75.6%

Quality32/100

Watch 2561 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$4.03 – HK$7.62

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price +13.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$19.24 – HK$51.75 · fair‑value band HK$4.03 – HK$7.62 · the HK$25.00 price screens above the HK$6.10 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2561 (2561) currently trades at HK$25.00, while our model-based Fair Value estimate is HK$6.10 — implying the stock looks roughly 75.6% overvalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at HK$136K. Revenue declined 68.6% year over year. It earns a return on equity of -50.5%. The balance sheet holds a net cash position of HK$456M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$136K

Revenue growth (YoY) -68.6%

Return on equity -50.5%

Free cash flow −HK$450M FY2025

Operating margin 17,848%

EPS (TTM) HK$-1.18

More key figures

Net cash HK$456M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

2561 reported revenue of HK$161K in FY2025 versus −HK$2.3M in FY2022. Reported net income was −HK$247M in FY2025.

Revenue

FY22 −HK$2.3M

FY23 −HK$1.7M

FY24 HK$2.8M

FY25 HK$161K

Net income

FY22 −HK$289M

FY23 −HK$250M

FY24 −HK$182M

FY25 −HK$247M

Is 2561 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2561 (2561) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$6.10 versus a price of HK$25.00 — about −76% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2561?

Our model-based fair value for 2561 is HK$6.10 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$25.00.

What is the quality score of 2561?

2561 has a Quality Score of 32/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2561 (2561)?

2561 reported trailing-twelve-month revenue of about HK$136K (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2561?

The net profit margin of 2561 is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.